BTBP: Recently officially launched Phase III clinical trials for human prothrombin complex

BTBP announced that its subsidiary, China National Pharmaceutical Group Wuhan Biological Products Co., Ltd., has completed the clinical ethical review and preparations for clinical enrollment for the human prothrombin complex it developed, and has officially launched Phase III clinical trials recently. This product is mainly used for the treatment of congenital and acquired deficiencies of coagulation factors II, VII, IX, and X, including Hemophilia B, anticoagulant overdose, and vitamin K deficiency. Currently, several companies in the domestic market produce this product, and there are also several multinational companies producing it in the international market. However, this product still needs to complete Phase III clinical trials and submit a drug marketing authorization application, among other procedures, and there are many internal and external uncertainties. Investors are advised to pay attention to investment risks